Neutralizing Antibodies to SARS‐CoV‐2 Selected from a Human Antibody Library Constructed Decades Ago

Min Qiang(ShanghaiTech University), Peixiang Ma(ShanghaiTech University), Yu Li(Chinese Academy of Sciences), Hejun Liu(Scripps Research Institute), Adam Harding(University of Oxford), Chenyu Min(PDX Pharmaceuticals (United States)), Fulian Wang(Chinese Academy of Sciences), Lili Liu(ShanghaiTech University), Meng Yuan(Scripps Research Institute), Qun Ji(ShanghaiTech University), Pingdong Tao(Chinese Academy of Sciences), Xiaojie Shi(ShanghaiTech University), Zhean Li(ShanghaiTech University), Teng Li(Chinese Academy of Sciences), Xian Wang(Chinese Academy of Sciences), Yu Zhang(ShanghaiTech University), Nicholas C. Wu(Scripps Research Institute), Chang‐Chun D. Lee(Scripps Research Institute), Xueyong Zhu(Scripps Research Institute), Javier Gilbert‐Jaramillo(University of Oxford), Chuyue Zhang(Chinese Academy of Sciences), Abhishek Saxena(ShanghaiTech University), Xingxu Huang(ShanghaiTech University), Hou Wang(Shanghai Sixth People's Hospital), William James(University of Oxford), Raymond A. Dwek(Science Oxford), Ian A. Wilson(Scripps Research Institute), Guang Yang(ShanghaiTech University), Richard A. Lerner(Scripps Research Institute)
Advanced Science
October 29, 2021
Cited by 19Open Access
Full Text

Abstract

Combinatorial antibody libraries not only effectively reduce antibody discovery to a numbers game, but enable documentation of the history of antibody responses in an individual. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has prompted a wider application of this technology to meet the public health challenge of pandemic threats in the modern era. Herein, a combinatorial human antibody library constructed 20 years before the coronavirus disease 2019 (COVID-19) pandemic is used to discover three highly potent antibodies that selectively bind SARS-CoV-2 spike protein and neutralize authentic SARS-CoV-2 virus. Compared to neutralizing antibodies from COVID-19 patients with generally low somatic hypermutation (SHM), these three antibodies contain over 13-22 SHMs, many of which are involved in specific interactions in their crystal structures with SARS-CoV-2 spike receptor binding domain. The identification of these somatically mutated antibodies in a pre-pandemic library raises intriguing questions about the origin and evolution of these antibodies with respect to their reactivity with SARS-CoV-2.


Related Papers

No related papers found

Powered by citation graph analysis